pharmaphorum
JUNE 8, 2022
Patients also have to undergo lymphodepleting chemotherapy to help prepare the body for the CAR-T cells. With Lunsumio, patients do not have to wait to start treatment and avoid the need for chemotherapy, which can sometimes not be an option at all for people who are frail.
STAT
NOVEMBER 12, 2024
The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily. AstraZeneca had to resubmit a closely watched medicine for U.S. Finally, AstraZeneca plans to invest $3.5 Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 19, 2021
ORR in patients previously treated with chemotherapy. billion in 2026 sales for Retevmo and $723 million for Gavreto, although that was before Roche lent its marketing muscle to the Blueprint drug. The median duration of response still hasn’t been reached for the treatment-naïve group in the ongoing trial, with a 22.3
pharmaphorum
FEBRUARY 14, 2022
Padcev (enfortumab vedotin) is already approved as a second-line therapy for urothelial carcinoma (UC) after cisplatin chemotherapy and immunotherapy with checkpoint inhibitors, but Seagen and Astellas are working towards earlier use of the drug. billion-a-year product in 2026, according to GlobalData.
pharmaphorum
APRIL 25, 2022
Analysts at Evaluate are predicting mosunetuzumab could make more than $500 million in sales in 2026, although other predictions go as high as $1 billion.
pharmaphorum
OCTOBER 11, 2020
The phase 3 PENELOPE-B trial was testing the CDK4/6 inhibitor as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant (pre-surgery) chemotherapy, but failed to show an improvement on the main measure of improved disease-free survival (iDFS).
Roots Analysis
OCTOBER 4, 2023
One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy. during the period 2023-2035.
Expert insights. Personalized for you.
105 
Let's personalize your content